Grant Bristol Myers Squibb CO Transaction History

Grant

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	BUY	$57.89 - $64.73 $810 - $906	14 Added 0.38%	3,709 $215,000
Q2 2023 Jul 19, 2023	BUY	$63.71 - $70.74 $235,408 - $261,384	3,695 New	3,695 $236,000
Q4 2022 Jan 10, 2023	SELL	$68.48 - $81.09 $50,606 - $59,925	-739 Reduced 16.76%	3,669 $0
Q3 2022 Nov 02, 2022	BUY	$0.13 - $76.84 $1 - $845	11 Added 0.25%	4,408 $320,000
Q2 2022 Jul 20, 2022	BUY	$72.62 - $79.98 $798 - $879	11 Added 0.25%	4,397 $329,000
Q1 2022 Apr 25, 2022	BUY	$61.48 - $73.72 $737 - $884	12 Added 0.27%	4,386 $335,000
Q4 2021 Jan 13, 2022	BUY	$53.63 - $62.52 $14,104 - $16,442	263 Added 6.4%	4,374 $286,000
Q3 2021 Oct 27, 2021	BUY	$59.17 - $69.31 $591 - $693	10 Added 0.24%	4,111 $237,000
Q2 2021 Aug 05, 2021	BUY	$61.91 - $67.42 $6,933 - $7,551	112 Added 2.81%	4,101 $275,000
Q1 2021 May 04, 2021	BUY	$59.34 - $66.74 $45,157 - $50,789	761 Added 23.57%	3,989 $249,000
Q4 2020 Jan 15, 2021	BUY	$57.74 - $65.43 $186,384 - $211,208	3,228 New	3,228 $208,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Grant, based on Form 13F filings with the SEC.

Stay updated on Grant with notifications on news.